• In May 2026, Workday opposed two shareholder proposals on demographic employee-retention disclosure and dual‑class vote reporting, while partner QGenda announced a new integration to unify healthcare workforce scheduling with Workday Human Capital Management.
• These moves highlight how Workday is balancing investor demands for transparency with efforts to deepen its ecosystem in complex, regulation‑heavy sectors like healthcare.
• Next, we’ll examine how the healthcare‑focused QGenda integration could influence Workday’s investment narrative around AI-enabled workforce management.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Workday Investment Narrative Recap

To own Workday, you need to believe its cloud HR and finance platform can stay central as organizations adopt AI driven workforce tools, even with rich valuation and tougher competition. The immediate catalyst is broadening AI and partner adoption, while a key risk is rising expectations around governance, disclosure, and compliance. The latest proxy fights over retention and voting transparency look more reputational than fundamental near term, but could shape future ESG and governance debates.

The QGenda integration is especially relevant here, because it ties Workday Human Capital Management into healthcare scheduling, time tracking, and payroll in one workflow. That speaks directly to Workday’s AI and automation catalyst in regulated sectors like healthcare and government, where complex labor rules and compliance needs can make unified data and real time visibility a differentiator, even as regulatory and operational risks remain front of mind.

Yet while the product story looks appealing, investors should also be aware that...

Workday’s narrative projects $13.1 billion revenue and $2.1 billion earnings by 2029. This requires 11.1% yearly revenue growth and an earnings increase of about $1.4 billion from $693.0 million today.

Uncover how Workday's forecasts yield a $179.22 fair value, a 40% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting Workday to reach about US$14.0 billion in revenue and US$2.6 billion in earnings by 2029, so if AI adoption or partner led growth in areas like healthcare stalls, your view on the stock could look very different from theirs.

Explore 11 other fair value estimates on Workday - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Workday research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Workday research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Workday's overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.